Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...

TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Citi analyst Patrick Donnelly lowered the firm’s price target on 10x Genomics (TXG) to $20 from $23 and keeps a Buy rating on the shares ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Real-time index price for TSX American Preferred Stock Index (STNC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Shares of Torex Gold Resources Inc. (TSE:TXG – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are covering the stock, MarketBeat reports. Four ...